68Ga-NOTA PET imaging for gastric emptying assessment in mice

Xueyan Chen1†, Yu Liu2†, Donghui Pan2, Maoyu Cao1, Xinyu Wang2, Lizhen Wang2, Yuping Xu2, Yan Wang2, Junjie Yan2, Juan Liu1,3* and Min Yang2*

Abstract

Background: Positron emission tomography (PET) has the potential for visualization and quantification of gastric emptying (GE). The traditional Chinese medicine (TCM) has been recognized promising for constipation. This study aimed to establish a PET imaging method for noninvasive GE measurement and to evaluate the efficacy of a TCM on delayed GE caused by constipation using PET imaging.

Methods: [68Ga]Ga-NOTA was synthesized as the tracer and sesame paste with different viscosity were selected as test meals. The dynamic PET scans were performed after [68Ga]Ga-NOTA mixed with test meals were administered to normal mice. Two methods were utilized for the quantification of PET imaging. A constipation mouse model was treated with maren chengqi decoction (MCD), and the established PET imaging scans were performed after the treatment.

Results: [68Ga]Ga-NOTA was synthesized within 20 min, and its radiochemical purity was > 95%. PET images showed the dynamic process of GE. %ID/g, volume, and total activity correlated well with each other. Among which, the half of GE time derived from %ID/g for 4 test meals were 3.92 ± 0.87 min, 13.1 ± 1.25 min, 17.8 ± 1.31 min, and 59.7 ± 3.11 min, respectively. Constipation mice treated with MCD showed improved body weight and fecal conditions as well as ameliorated GE measured by [68Ga]Ga-NOTA PET.

Conclusions: A PET imaging method for noninvasive GE measurement was established with stable radiotracer, high image quality, and reliable quantification methods. The efficacy of MCD on delayed GE was demonstrated using PET.

Keywords: Gastric emptying, Positron emission tomography, [68Ga]Ga-NOTA, Constipation, Traditional Chinese medicine

Background

Gastrointestinal motility disorders such as gastroparesis, functional dyspepsia, and constipation, affect the life quality of a huge population worldwide and cause considerable medical expenses and economic burden [1, 2].

Gastric emptying (GE) is one of the most important parts of gastrointestinal motility. Since accelerated, normal, and delayed GE cannot be reliably differentiated based on specific symptoms, objective measurement of GE is required [3]. Besides, abnormal GE frequently occurs in certain diseases such as diabetes, critically ill, systematic sclerosis, and Parkinson's disease, and the altered GE may be an important mechanism for some effective medications [4–10]. Therefore, it is important to visualize and quantify GE.

At present, accurate GE measurement remains challenges. The indirect methods such as 13C breathe test...
and paracetamol absorption test require breathe or blood analysis. These methods can be disrupted by hyperglycemia and impaired liver or kidney functions [3, 11, 12]. Conventional imaging modalities such as ultrasonography, bioluminescence, and magnetic resonance imaging (MRI) are limited by temporal or spatial resolution, quantitative capability, or low availability [13–15]. Some alternative methods were put forward in recent years and showed potential for the effective visualization and localization of solid dosage forms in the intestinal tract of rats [16]. Scintigraphy, a functional imaging modality combined with radiotracers (e.g., $^{99m}$Tc-phytate, $^{99m}$Tc-Tc-DTPA, and $^{99m}$Tc-sulphur colloid), is currently the reference standard for noninvasive GE evaluation which can provide direct and comprehensive visualization for GE [17].

Although scintigraphy has been widely recognized and standardized [18], few studies explored the value of positron emission tomography (PET), another functional imaging modality using radiotracers, for GE measurement. The imaging manners of PET also makes it have the advantages of scintigraphy. They are both direct measures for functional information. Both of them can visualize and determine the intragastric distribution. Besides, PET has better quantification capability and image quality and is considered to be one of the most advanced modalities for medical imaging [19–21]. Previous studies have demonstrated the potential of PET for investigating gastrointestinal absorption and pharmacokinetic profiles of drugs [22–24]. However, no PET tracer has been tested for the direct GE measurement. Perhaps the primary concern for PET is the low cost-effectiveness, but this concern can be mitigated by using more cost-effective PET radionuclides. At present, PET usually uses $^{18}$F as the radionuclide which is produced by the cyclotron. Just like $^{99m}$Tc, $^{68}$Ga is produced by the generator, which has the advantages of simple operation, low economic and site burdens, and no need for additional radiation shielding and high-skilled operators for the cyclotron [25]. Therefore, $^{68}$Ga has been currently one of the most popular PET radionuclides in both basic research and clinical applications.

Constipation has negative impacts on life quality and is a considerable burden on health-care resources. The median prevalence of constipation is >16% worldwide. Besides, constipation is usually associated with other gastrointestinal disorders and increased prevalence of psychological distress [26, 27]. In recent years, research on the treatment of constipation using traditional Chinese medicine (TCM) has increased significantly and shown promising results [28, 29]. Maren Chengqi decoction (MCD) is a modified Chinese herbal formula based on Chengqi decoction. Chengqi decoction is a well-known TCM that showed efficacy for the treatment of gastrointestinal disorders in Chinese research [30–33]. Maren (seeds of Cannabis sativa L.) has the effects of laxative and is usually used for the treatment of blood deficiency and constipation in TCM [34–36]. However, it remains unclear whether these TCMs can ameliorate GE in constipation and other gastrointestinal disorders. In this study, the primary aim was to establish an available PET imaging method for accurate GE measurement using radionuclide $^{68}$Ga. Then, we would like to evaluate the improvement of MCD on delayed GE caused by constipation using this established PET imaging method.

**Methods**

**Animals and generals**

ICR mice used in this study (8–10 weeks age, half male and half female) were purchased from Changzhou Cavens Animal Co., Ltd. and housed in the Laboratory Animal Center of Jiangsu Institute of Nuclear Medicine under a temperature-controlled (23 °C ± 2 °C) and humidity-controlled (~50%) condition. Mice were free to access standard autoclaved rodent food [37] and water and were maintained in a 12-h light/dark cycle. All animal experiments were approved by the Laboratory Animal Management and Ethics Committee of Jiangsu Institute of Nuclear Medicine (Ethical Committee Number: JSINM-2018-043). After the experiments, mice were euthanized by cervical dislocation. All reagents, unless otherwise stated, were purchased from commercial suppliers and used without further purification. $^{68}$Ga$^{3+}$ for the radiolabeling was obtained from $^{68}$Ge/$^{68}$Ga generators (ITG, Germany). $^{99m}$Tc-DTPA which had satisfied the clinical requirement was generously provided by the Department of Nuclear Medicine, Jiangyuan Hospital. All experiments were performed blindly among researcher.

**Preparation of $[^{68}\text{Ga}]$Ga-NOTA**

The fresh $^{68}$Ga$^{3+}$ was obtained in the form of $[^{68}\text{Ga}]$GaCl$_3$ which was eluted from $^{68}$Ge/$^{68}$Ga generators with 4 mL 0.05 M HCl. Among them, the 1.5 mL fraction with the highest radioactivity (~370 MBq) was used for further radiolabeling. Then, 94 μL 1 M sodium acetate buffer was added into $[^{68}\text{Ga}]$GaCl$_3$ solution, followed by 50 μg maleimide-NOTA (CheMatech, France), and the mixture was heated at 97 °C for 10 min. The product was captured on a C18 column (Agilent, USA) using 10 mL deionized water and then eluted with 0.3 mL 10 mM HCl-containing ethanol. The radiochemical purity and in vitro stability in simulated gastric fluid [38] of the final product were measured by a radio-HPLC (Waters, USA) based on the protocol of previous studies [39].
Preparation of test meals
We prepared 4 types of test meals to determine the feasibility of $[^{68}\text{Ga}]\text{Ga}$-NOTA PET for GE evaluation. These test meals could represent liquid food (G1: 2 mL saline), semi-fluid food (G2: 0.5 g black sesame paste with 2 mL saline), fluid food (G3: 1 g black sesame paste with 2 mL saline), and semi-solid food (G4: 1.5 g black sesame paste with 2 mL saline), respectively. The edible black sesame paste (Nanfang, China) we used in this study was in line with Chinese dietary habits and made up of rice, black sesame ($\geq$ 21.5%), sesame, maltodextrin, xylitol, walnuts, and peanuts. Each 40 g of them contained 696 kJ energy, 3.6 g protein, 5.2 g fat, 26 g carbohydrates, 1.8 g sugar, 40 mg sodium, 60 mg calcium, and 0.6 mg iron. The viscosity of these test meals was measured by a Rheometer (HAAKE, Germany). Finally, $[^{68}\text{Ga}]\text{Ga}$-NOTA or $[^{99}\text{mTc}]\text{Tc}$-DTPA was added into these test meals before PET or scintigraphy scans.

PET scans
All PET scans were performed on an Inveon microPET scanner (Siemens Medical Solutions, Germany). Mice were fasted for at least 12 h before scans. Since previous studies demonstrated that anesthesia might have non-negligible effects on the gastrointestinal motility of mice, the mice under conscious state were immobilized in a small-animal retainer on the scanning bed during scans [23]. Meanwhile, a dedicated observer always paid attention to the conditions of the mice, and the scans would be terminated immediately if the mice showed instability (rapid/weak breathing, limb convulsions, etc.). The four test meals (0.3 mL) were mixed with 2.59 MBq $[^{68}\text{Ga}]\text{Ga}$-NOTA and intragastrically administered to the mice ($n=4$/group) randomly at a constant rate within 10 s. The dynamic image acquisitions were continued from the tip of the noses to distal femurs in order to capture the entire mice in the optimal field of view. We manually overlaid the PET images onto the selected CT image.

Image data analysis
We utilized two methods for the quantification of PET images. For the first method, regions of interest (ROIs) for the entire stomach were manually drawn on the averaged dynamic PET image of each mouse using ASIPro version 6.8. Then these ROIs were used to extract time-activity curves (TAC) of all dynamic images of each mouse and the radioactivity in ROIs was represented by image-derived percentage injected dose per gram (%ID/g). The half of GE time ($T_{1/2}$) was defined as the reduction in intragastric radioactivity to half of the highest radioactivity on the TAC at this time point. The GE rate at any time point (GERt) was calculated as $\text{GERt} = \left(1 - \frac{\%\text{ID/g(t)}}{\%\text{ID/g(max)}}\right) \times 100\%$ and %ID/g(t) represented the radioactivity at specific time points while %ID/g(max) represented the highest radioactivity on the TAC. For the second method, reconstructed images were processed by PMOD software version 3.8 to accurately measure the volume of gastric content and calculate the total radioactivity. The 3D volumes of interest (VOIs) in stomach of each mouse was automatically extracted using PBAS module, then the average volume and PET unit values could be obtained. The total activity could be calculated as total activity = average PET unit value $\times$ conversion factor $\times$ 0.037 $\times$ volume. Then $T_{1/2}$ and GER were calculated based on total activity and volume, respectively. Finally, we would evaluate the linear correlations between the quantified results obtained from PMOD and ASIPro.

CT scans
For better visualization and anatomical matching of PET images, we performed micro-computed X-ray tomography (microCT) scans for these mice. Mice were anesthetized with 1.5–2.5% isoflurane/oxygen mixture before scanning and the anesthesia was maintained during the scans. The mice were lying prone on the scanning bed and the posture remained the same as that of the PET scans. All scans were performed at a tube voltage of 40 kV and a current of 200 μA. CT scans were performed from the tip of the noses to distal femurs in order to capture the entire mice in the optimal field of view. We manually compared the acquired CT images and selected one frame that best fitted the position and posture of PET scans. Finally, we manually overlaid the PET images onto the selected CT image.

Biodistribution
The mice were sacrificed at 1 h after intragastric administration of $[^{68}\text{Ga}]\text{Ga}$-NOTA mixed with 4 test meals ($n=4$/group). The administered dose of radiotracer was the same in different groups. The samples of major tissues and organs including blood, heart, liver, spleen, lung, kidney, stomach, duodenum, colon, bladder, pancreas, muscle, and bone were dissected and weighed. The radioactivity of each sample was measured by a γ-counter and the quantification of these radioactive uptakes was expressed in %ID/g.

Scintigraphy scans
We performed scintigraphy scans for the mice on a clinical SPECT scanner (Philips, Netherlands) in Jiangyuan Hospital. In brief, the fasted mice were immobilized on the scanning bed under conscious state. The prepared.
liquid test meals (0.3 mL) were mixed with 3.7 MBq \(^{99m}\text{Tc}\) Tc-DTPA and intragastrically administered to the mice (n = 5) at a constant rate within 10 s, and then 30-min dynamic image acquisitions were conducted immediately with images acquired 1 frame/min. While the mice were intragastrically administered, we placed a cylindrical bottle with 0.3 mL liquid test meals mixed with 3.7 MBq \(^{99m}\text{Tc}\) Tc-DTPA on the upper right side of the mice as a reference. So that we could have intuitive comparisons between the radioactivity in the stomach and the standard. ROIs were drawn manually and the total radioactive counts in these ROIs were calculated.

Mouse model of constipation

Fifty mice were randomly selected for the induction of constipation model, and another ten mice were selected as the healthy control group. According to the TCM methods and previous studies \([40, 41]\), the constipation model was induced by a kind of Chinese herbal decoction combined with loperamide hydrochloride (Janssen, China) as well as a moderate restriction of water. Briefly, the volatile oil of dried ginger, cinnamon, evodia rutaecarpa, and pepper were extracted. Meanwhile, the aconite was boiled with water for 30 min, then the residue of the extracted volatile oil was added and boiled for another 30 min. The product was filtered and the filtered liquid was repeatedly boiled and filtered twice for 30 min each time. The final filtrate was concentrated to ~1 g/mL using a rotary evaporator (IKA, Germany) and then mixed with the extracted volatile oil which was dissolved in Tween-80 (1:2). The dose for constipation induction was 2 mL/100 g body weight (i.e., 2 g herbal decoction and 0.2 mg loperamide hydrochloride) once daily for 10 days. The control group was administered with 0.9% saline at the same dose once daily for 10 days. The body weight, fecal quantity, and fecal moisture of mice were measured every day. \(^{68}\text{Ga}\) Ga-NOTA PET dynamic scans using liquid test meals were performed after the treatment was finished immediately.

Statistical analysis

The data were presented as mean ± SD. Statistical analysis was performed using Stata/SE 12.0. The differences between groups were analyzed by student t-test and one-way ANOVA with Bonferroni post-hoc test. Pearson's correlation coefficient was used to evaluate the association between radioactivity calculated by ASIPro and PMOD. Results were considered statistically significant as p < 0.05.

Results

Radiochemistry and in vitro stability

The synthesis of \(^{68}\text{Ga}\) Ga-NOTA was completed within 20 min with a radiochemical purity > 95% (Fig. 1a). The retention times of \(^{68}\text{Ga}\) Ga-NOTA in HPLC were approximately 4.7 and 11.6 min, respectively. After incubated in simulated gastric fluid for 2 h, the radiochemical purity of \(^{68}\text{Ga}\) Ga-NOTA was still higher than 90% (Fig. 1b).

Test meals

The viscosity of 4 test meals decreased with increasing shear rates (Fig. 1c). At room temperature, when the shear rate was about 0.091 1/s (near infinitesimal), the viscosity of each test meal were 0.26 ± 0.05 Pa·s (G1), 0.137 ± 0.020 × 10^3 Pa·s (G2), 1.22 × 10^3 ± 0.238 × 10^3 Pa·s (G3), and 2.34 × 10^3 ± 0.387 × 10^3 Pa·s (G4), respectively (Fig. 1d).

PET images and quantification

The dynamic accumulation and emptying process of 4 test meals in the stomach was presented on the PET images (Fig. 2). Although the 4 groups of mice reached the maximum radioactivity in the stomach at similar time points by gavage, the PET images showed that the time points at which different contents were discharged from
the stomach were significantly different. At 30 s after administration, the duodenum in the G1 group showed radioactive uptake, while the radioactivity in the G2 and G3 groups appeared to be confined to the stomach at 42 s and the G4 group still could not see the test meal discharged from the stomach at 270 s. At 1 h after administration, the radioactivity with test meal in the stomach of the G1 group was almost completely emptied, however, the tracer of the G4 group still had lots of accumulation in the stomach.

As the viscosity of the test meal increased, the radiotracer remained in the stomach longer (Fig. 3a, Additional file 1: Figure S1A), and the GER calculated based on %ID/g was lower (Fig. 3b, Additional file 1: Figure S1D). Figure 3c showed significant differences in $T_{1/2}$ between any two test meals and the quantitative $T_{1/2}$ were $3.92 \pm 0.87$ min, $13.1 \pm 1.25$ min, $17.8 \pm 1.31$ min, and $59.7 \pm 3.11$ min for G1, G2, G3, and G4, respectively. Furthermore, PMOD was used to calculate the dynamic changes in the volume and total radioactivity of gastric contents during PET imaging. Similarly, all test meals rapidly reached their maximum volume and radioactivity in the stomach and had almost the same maximum radioactivity (Fig. 3d, g, Additional file 1: Figure S1E).
However, the time points at which the volume and radioactivity began to decrease in the stomach and their downward trends within 1 h were different among 4 groups. It was shown that liquid meal (G1) had the fastest emptying process of content volume and total activity while the downward trends were closer to the linear form with the increase of the viscosity of test meals. The changes in GER calculated by volume and radioactivity within 1 h were the same as their corresponding indexes. The changes in GER calculated by volume and radioactivity within 1 h were the same as their corresponding indexes. Besides, the T_{1/2} based on volume and total activity both showed significant differences among these test meals (Fig. 3c, f, i). *p < 0.05, **p < 0.01, ***p < 0.001, and p values in c, f, and i were calculate by one-way ANOVA with Bonferroni post-hoc test.

Finally, we analyzed the correlations among %ID/g, volume, and total activity (Fig. 4). Whether it was the dynamic changes of the 3 parameters (Fig. 4a–c) or the GERs calculated by them (Fig. 4d–f), it all showed high correlations between them (p < 0.0001), indicating that the %ID/g calculated using the simpler manually delineated ROIs could substitute the volume or total activity calculated by PMOD to reflect the GE process. Besides, the excellent correlation between volume and total activity demonstrated the uniform distribution of the radiotracer in the test meals.

**Biodistribution**

At 1 h after administration, the radioactivity mainly accumulated in the stomach and duodenum (Table 1). With the increase of the viscosity of test meals, there was significantly higher radioactivity in the stomach and duodenum (p < 0.05), indicating the slower GE process in the group with higher viscosity of test meals. Besides, the radioactivity in the blood of all mice was extremely low, demonstrating the promising in vivo stability of [68Ga] Ga-NOTA in the gastric environment.
Scintigraphy scans
After intragastric administration of $[^{99m}Tc]$Tc-DTPA mixed with liquid test meal, the total radioactive counts in the stomach acquired from scintigraphy decreased rapidly and reached equilibrium at 15 min (Additional file 2: Figure S2), and these results were similar to those shown by $[^{68}Ga]$Ga-NOTA PET. Due to the limited image quality and quantification capability, we didn't calculate the GER and $T_{1/2}$ measured by scintigraphy.

MCD ameliorated constipation symptoms
As shown in Fig. 5a–c and Additional file 3: Figure S3A–D, the body weight, fecal quantity, and fecal moisture of constipation mice decreased significantly during modeling period. On the contrary, the fecal quantity and moisture of control mice remained stable and their body weight increased significantly. On the day 10 of modeling, there were significant differences in body weight, fecal quantity, and fecal moisture between these two
respectively. They were all significantly different from Additional file 4: Figure S4). As shown in Fig. 6i, the T1/2 for control, high, middle, low doses of MCD, and magnesium sulfate group were 4.13 ± 0.25, 1.41 ± 0.11, 0.50 ± 0.10, and 0.29 ± 0.14 min, respectively. They were all significantly different from those of untreated constipation mice (Fig. 5d–f, Additional file 3: Figure S3E–G).

PET evaluation of MCD therapy for constipation

The representative PET images were shown in Fig. 6a–f. The time point that radiotracer began to be discharged from the stomach were earlier in control mice and constipation mice with treatments than untreated constipation mice. Control group had the fastest declines in GER, while untreated constipation group had the slowest reductions. The GER of treatment groups also decreased faster than untreated constipation group. Control group had the fastest declines in GER, while untreated constipation group had the slowest reductions. The GER of treatment groups also decreased faster than untreated constipation group. Control group had the fastest declines in GER, while untreated constipation group had the slowest reductions. The GER of treatment groups also decreased faster than untreated constipation group. Control group had the fastest declines in GER, while untreated constipation group had the slowest reductions. The GER of treatment groups also decreased faster than untreated constipation group. Control group had the fastest declines in GER, while untreated constipation group had the slowest reductions. The GER of treatment groups also decreased faster than untreated constipation group. Control group had the fastest declines in GER, while untreated constipation group had the slowest reductions. The GER of treatment groups also decreased faster than untreated constipation group. Control group had the fastest declines in GER, while untreated constipation group had the slowest reductions. The GER of treatment groups also decreased faster than untreated constipation group. Control group had the fastest declines in GER, while untreated constipation group had the slowest reductions. The GER of treatment groups also decreased faster than untreated constipation group. Control group had the fastest declines in GER, while untreated constipation group had the slowest reductions. The GER of treatment groups also decreased faster than untreated constipation group. Control group had the fastest declines in GER, while untreated constipation group had the slowest reductions. The GER of treatment groups also decreased faster than untreated constipation group. Control group had the fastest declines in GER, while untreated constipation group had the slowest reductions. The GER of treatment groups also decreased faster than untreated constipation group. Control group had the fastest declines in GER, while untreated constipation group had the slowest reductions. The GER of treatment groups also decreased faster than untreated constipation group. Control group had the fastest declines in GER, while untreated constipation group had the slowest reductions. The GER of treatment groups also decreased faster than untreated constipation group. Control group had the fastest declines in GER, while untreated constipation group had the slowest reductions. The GER of treatment groups also decreased faster than untreated constipation group. Control group had the fastest declines in GER, while untreated constipation group had the slowest reductions. The GER of treatment groups also decreased faster than untreated constipation group. Control group had the fastest declines in GER, while untreated constipation group had the slowest reductions. The GER of treatment groups also decreased faster than untreated constipation group. Control group had the fastest declines in GER, while untreated constipation group had the slowest reductions. The GER of treatment groups also decreased faster than untreated constipation group. Control group had the fastest declines in GER, while untreated constipation group had the slowest reductions. The GER of treatment groups also decreased faster than untreated constipation group. Control group had the fastest declines in GER, while untreated constipation group had the slowest reductions. The GER of treatment groups also decreased faster than untreated constipation group. Control group had the fastest declines in GER, while untreated constipation group had the slowest reductions. The GER of treatment groups also decreased faster than untreated constipation group. Control group had the fastest declines in GER, while untreated constipation group had the slowest reductions. The GER of treatment groups also decreased faster than untreated constipation group. Control group had the fastest declines in GER, while untreated constipation group had the slowest reductions. The GER of treatment groups also decreased faster than untreated constipation group. Control group had the fastest declines in GER, while untreated constipation group had the slowest reductions.

Discussion

In this study, a noninvasive PET imaging method was used in this study can be easily synthesized within 20 min and without further purification. These advantages would improve the cost-effectiveness of PET for GE measurement. In addition, the shorter half-life of 68Ga (67.8 min) compared to 99mTc (6.02 h) and 18F (110 min) would reduce the exposure duration. Moreover, the high image quality shown in this study makes it possible to flexibly reduce the exposure duration.

Table 1 Biodistribution of 68GaGa-NOTA in the mice at 60 min after administration (n = 4/group)

| Tissue            | G1 (%ID/g) ± SD | G2 (%ID/g) ± SD | G3 (%ID/g) ± SD | G4 (%ID/g) ± SD |
|-------------------|----------------|----------------|----------------|----------------|
| Blood             | 0.23 ± 0.06    | 0.22 ± 0.11    | 0.31 ± 0.04    | 0.29 ± 0.10    |
| Heart             | 0.31 ± 0.20    | 0.35 ± 0.14    | 0.57 ± 0.34    | 0.50 ± 0.44    |
| Liver             | 0.26 ± 0.10    | 0.19 ± 0.08    | 0.27 ± 0.13    | 0.26 ± 0.14    |
| Spleen            | 0.32 ± 0.19    | 0.63 ± 0.35    | 0.62 ± 0.10    | 0.73 ± 0.62    |
| Lung              | 0.26 ± 0.10    | 0.41 ± 0.40    | 0.35 ± 0.08    | 0.81 ± 0.55    |
| Kidney            | 0.32 ± 0.14    | 0.25 ± 0.13    | 0.43 ± 0.21    | 0.67 ± 0.32    |
| Stomach*          | 11.4 ± 2.20    | 34.6 ± 19.4    | 42.3 ± 16.0    | 85.2 ± 33.3    |
| Duodenum          | 3.04 ± 2.58    | 6.24 ± 5.89    | 11.4 ± 5.20    | 13.5 ± 5.83    |
| Colon             | 0.23 ± 0.11    | 1.21 ± 1.57    | 1.39 ± 1.41    | 0.52 ± 0.24    |
| Bladder           | 1.26 ± 0.91    | 1.34 ± 0.72    | 1.94 ± 0.59    | 2.07 ± 0.76    |
| Pancreas          | 0.25 ± 0.13    | 0.29 ± 0.08    | 0.35 ± 0.17    | 0.31 ± 0.14    |
| Muscle            | 0.70 ± 0.79    | 0.50 ± 0.67    | 0.73 ± 0.44    | 0.59 ± 0.40    |
| Bone              | 0.59 ± 0.34    | 0.63 ± 0.37    | 0.68 ± 0.39    | 0.58 ± 0.36    |

Data were represented as mean ± SD
* p < 0.05 among the 4 groups calculated by one-way ANOVA
that PET objectively quantified the GE process after MCD treatment and indicated that MCD can improve the GE in constipation at low dosage. In addition, this study also showed that MCD had the ability to ameliorate constipation. Although lots of TCMs showed efficacy for the treatment of gastrointestinal motility disorders, only a few of the underlying mechanisms of these treatments have been explored [49]. Among them, many studies chose to measure the changes in GE during treatment to demonstrate their efficacy [50–52]. The feasibility and availability of PET for GE measurement established in this study would provide a powerful tool for these pharmacological studies.

Our study also has some limitations. Firstly, we did not conduct scintigraphy scans on animal-used equipment. Our data showed the stable visualization and quantification ability and promising potential of PET for the evaluation of GE. Further experiments were needed to directly compare the differences between PET and scintigraphy in GE measurement. Besides, due to the limitation of microPET equipment used in this study, the CT images of mice were manually...
overlapped on PET images, which might impair some image information. However, we believe that the direct fusion of PET and CT images will further demonstrate the excellent image quality and quantification capability of PET. Finally, the mechanism of MCD in relieving constipation was not clear. Whether the increased rate of GE in MCD was due to the nutritive value of MCD such as its oily components or the medicinal activity of MCD cannot be demonstrated based on existed data. Further pharmacological studies are needed to explore this issue.

Fig. 6  PET evaluation of MCD therapy for constipation. Representative PET images of control group (a), model group (b), high dose group (c), middle dose group (d), low dose group (e), and positive control group (f). The %ID/g (g), GER (h), and T1/2 (i) of 6 groups (n = 3/group). ***p < 0.001, and p values in i were calculated by one-way ANOVA with Bonferroni post-hoc test. GER, gastric emptying rate.
Conclusions
In summary, this study established a noninvasive PET imaging method for GE measurement in mice. The powerful quantification and visualization capabilities of PET made it a unique and important value for evaluating GE. Besides, the more cost-effective radiotracer and quantification method we explored overcame its shortcomings and made it more convenient for applications. The improvement of GE in constipation during MCD treatment was demonstrated by PET. These results demonstrated the feasibility and potential of PET for GE measurement.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12876-021-01642-7.

Additional file 1: Quantification of the first 3 min of dynamic PET images in 4 groups of mice (n=4/group).
Additional file 2: Results of scintigraphy.
Additional file 3: Fecal conditions of the mice.
Additional file 4: Quantification of the first 1.5 min of dynamic PET images in 6 groups of mice after treatment period (n=3/group).

Abbreviations
GE: Gastric emptying; MRI: Magnetic resonance imaging; PET: Positron emission tomography; TCM: Traditional Chinese medicine; MCD: Maren chengqi decoction; ROI: Region of interest; GER: Gastric emptying rate; TAC: Time-activity curve; T1/2: Half of GE time; CT: Computed tomography; SPECT: Single-photon emission computed tomography.

Acknowledgements
Not applicable.

Authors’ contributions
MY, JL, and XW designed research. XC, YL, MC, and DP conducted experiments. LW and XW reared and cared for the mice. YL and MY analyzed the data. YL and JY performed statistical analysis and designed research. XC, YL, MC, and DP conducted experiments. All authors read and approved the final manuscript.

Funding
This work was supported by National Key Research and Development Program (2016YFC1306600), National Significant New Drugs Creation Program (2017ZX09304021), National Natural Science Foundation (31971316 and 31671035), Jiangsu Provincial Medical Innovation Team (CXTDA2017024), National Natural Science Foundation (31971316 and 31671035), Jiangsu Provincial Medical Innovation Team (CXTDA2017024), and National Significant New Drugs Creation Program (2016YFC1306600). The authors declare that they have no competing interests.

Availability of data and materials
The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
All animal experiments were approved by the Laboratory Animal Management and Ethics Committee of Jiangsu Institute of Nuclear Medicine (Ethical Committee Number: JSINM-2018-043).

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Received: 28 May 2020 Accepted: 3 February 2021

References
1. Stanghellini V, Chan FK, Hasler WL, et al. Gastroduodenal disorders. Gastroenterology. 2016;150(6):1380–92.
2. Camilleri M, Ford AC, Mawe GM, et al. Chronic constipation. Nat Rev Dis Primers. 2017;3:17095.
3. Keller J, Bassotti G, Clarke J, et al. Expert consensus document: advances in the diagnosis and classification of gastric and intestinal motility disorders. Nat Rev Gastroenterol Hepatol. 2018;15(5):291–308.
4. Vijayvargiya P, Jamee-Oskooei S, Camilleri M, et al. Association between delayed gastric emptying and upper gastrointestinal symptoms: a systematic review and meta-analysis. Gut. 2019;68(3):804–13.
5. Greis C, Rasuly Z, Janosi RA, et al. Intestinal T lymphocyte homing is associated with gastric emptying and epithelial barrier function in critically ill: a prospective observational study. Crit Care. 2017;21(1):70.
6. Phillips LK, Deane AM, Jones KL, et al. Gastric emptying and glycaemia in diabetes and diabetes mellitus. Nat Rev Endocrinol. 2015;11(2):112–28.
7. Knudsen K, Szwebs M, Hansen AK, et al. Gastric emptying in Parkinson’s disease—a mini-review. Parkinsonism Relat Disord. 2018;55:18–25.
8. Lang Lehrskov L, Lyngbaek MP, Soederlund L, et al. Interleukin-6 delays gastric emptying in humans with direct effects on glycemic control. Cell Metab. 2018;27(6):1201-1-1201-203.
9. Vijayvargiya P, Camilleri M, Chedid V, et al. Effects of promotility agents on gastric emptying and symptoms: a systematic review and meta-analysis. Gastroenterology. 2019;156(6):1650–60.
10. Thomaides T, Karapanayiotides T, Zoukos Y, et al. Gastric emptying after semi-solid food in multiple system atrophy and Parkinson disease. J Neuro. 2005;252(9):1055–9.
11. Phillips LK, Rayner CK, Jones KL, et al. Measurement of gastric emptying in diabetes. J Diabetes Complicat. 2014;28(6):894–905.
12. Keller J, Andresen V, Wolter J, et al. Influence of clinical parameters on the results of 13C-octanoic acid breath tests: examination of different mathematical models in a large patient cohort. Neurogastroenterol Motil. 2009;21(10):1039-e1083.
13. Szarka LA, Camilleri M. Methods for measurement of gastric motility. Am J Physiol Gastrointest Liver Physiol. 2009;296(3):G461–75.
14. Roda A, Mezzanotte L, Aldini R, et al. A new gastric-emptying mouse model based on in vivo non-invasive bioluminescence imaging. Neurogastroenterol Motil. 2010;22(10):e117-e1288.
15. Schmidt PT, Abrahamsson H, Dolk A, et al. Methods to assess gastric motility and sensation. Scand J Gastroenterol. 2008;43(11):1285–95.
16. Gomez-Lado N, Seoane-Viano I, Matiz S, et al. Gastrintestinal tracking and gastric emptying of coated capsules in rats with or without sedation using CT imaging. Pharmaceutics. 2020;12(1):81.
17. Maurer AH. Gastrintestinal motility, part 1: esophageal transit and gastric emptying. J Nucl Med. 2015;56(8):1229–38.
18. Abell TL, Camilleri M, Donohoe K, et al. Consensus recommendations for gastric emptying scintigraphy: a joint report of the American Neurogastroenterology and Motility Society and the Society of Nuclear Medicine. Am J Gastroenterol. 2006;101(3):753–63.
19. Ge J, Zhang Q, Zeng J, et al. Radiolabeling nanomaterials for multimodal imaging: new insights into nuclear medicine and cancer diagnosis. Biomaterials. 2020;228:119553.
20. Conway J. Lung imaging—two dimensional gamma scintigraphy, SPECT, CT and PET. Adv Drug Deliv Rev. 2012;64(4):357–68.
21. LeBlanc AK, Peremans K. PET and SPECT imaging in veterinary medicine. Semin Nucl Med. 2014;44(1):47–56.
22. Goyanes A, Fernandez-Ferreiro A, Majeed A, et al. PET/CT imaging of 3D printed devices in the gastrointestinal tract of rodents. Int J Pharm. 2018;536(1):138–64.
23. Yamashita S, Takahama T, Katoaka M, et al. PET imaging of the gastrointestinal absorption of orally administered drugs in conscious and anesthetized rats. J Nucl Med. 2011;52(2):249–56.
24. Shingaki T, Takahama T, Wada Y, et al. Imaging of gastrointestinal absorption and biodistribution of an orally administered probe using positron emission tomography in humans. Clin Pharmacol Ther. 2012;91(4):653–9.
25. Amor-Coarasa A, Schoendorf M, Meckel M, et al. Comprehensive quality control of the ITG 68 Ge/68 Ga generator and synthesis of 68Ga-DOTATOC and 68Ga-PSMA-HBED-CC for clinical imaging. J Nucl Med. 2016;57(9):1402–5.
26. Rao SS, Rattanakovit K, Patcharatrakul T. Diagnosis and management of chronic constipation in adults. Nat Rev Gastroenterol Hepatol. 2016;13(5):295–305.
27. Belsey J, Greenfeld S, Candy D, et al. Systematic review: impact of constipation on quality of life in adults and children. Aliment Pharmacol Ther. 2010;31(9):938–49.
28. Gong H, Qin F, He H. Herbal formula modified Buzhong-Yiqi-Tang for functional constipation in adults: a meta-analysis of randomized controlled trials. Evid Based Complement Altern Med. 2018;2018:9602525.
29. Peng W, Liang H, Sibbritt D, et al. Complementary and alternative medicine use for constipation: a critical review focusing upon prevalence, type, cost, and users’ profile, perception and motivations. Int J Clin Pract. 2016;70(9):712–22.
30. Chen P, Jiang L, Geng H, et al. Effectiveness of Xinglouchengqi decoction on constipation in patients with acute ischemic stroke: a randomized controlled trial. J Tradit Chin Med. 2020;40(1):112–20.
31. Chu X, Zhou Y, Wang Y, et al. A study on effect of Chengqi Tang combined with enteral nutrition on enteral resuscitation in patients with severe traumatic brain injury. J New Chin Med. 2019;51(9):50–2.
32. Yu L, Zhuang S. Clinical study on transnasal ileus tube combined with enema with compound Dachengqi Tang for adhesive intestinal obstruction. Chin J Tradit Chin Med. 2019;57(8):120–3.
33. Ge H, Xu C, Chu L, et al. Effect of FuFang Dachengqi Decoction on the postoperative gastrointestinal motility in patients with esophageal cancer. Chin J Nurs. 2011;46(6):576–8.
34. Li D, Xie Z, Li Y, et al. Effect and safety of Maren Soft Capsule on constipation. Chin Tradit Herb Drugs. 2014;45(8):1126–8.
35. Cui J, Zheng Y. Clinic observation on efficacy of Maren Soft Capsule in prevention of constipation after anorectal operation. Chin Tradit Herb Drugs. 2016;47(3):466–8.
36. Chen Z, Jin Z, Yuan Y. Clinical observation of Maren Soft Capsule in treatment of stroke patients with constipation. Chin Tradit Herb Drugs. 2016;47(3):466–8.
37. Reeves PG, Nielsen FH, Fahey GC Jr. AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet. J Nutr. 1993;123(11):1939–51.
38. Pienaar JA, Singh A, Barnard TG. Acid-happy: survival and recovery of enteropathogenic Escherichia coli (EPEC) in simulated gastric fluid. Microb Pathog. 2019;128:396–404.
39. Xu Q, Zhu C, Xu Y, et al. Preliminary evaluation of 18F-fluorodeoxyglucose (FDG) and 18F-fluorodeoxyglucose (18F-FDG) in a patient with gastric cancer: a PET/CT and conventional imaging comparison. World J Gastroenterol. 2015;21(49):13771–6.
40. Wang J, Chen Y, Yuan ZM. Correlation between integrated pharmacokinetics and pharmodynamics of bile processed Rhizoma Coptidis in febrile rats. Acta pharm Sin. 2016;51(1):127–31.
41. Chen L, Zhang T, Peng C. Large intestineOFFicinalis to treatment of functional constipation in patients with acute ischemic stroke: a randomized controlled trial. J Tradit Chin Med. 2020;40(1):112–20.
42. Yen J, Wu D, Lin J, et al. Automated quantification of amyloid positron emission tomography: a comparison of PMOD and MIMneuro. Ann Nucl Med. 2016;30(10):682–9.
43. Velikan I. 68Ga-Based radiopharmaceuticals: production and application relationship. Molecules. 2015;20(12):1929–34.
44. Setiawan E, Wilson AA, Mizrahi R, et al. Role of translocator protein density, a marker of neuroinflammation, in the brain during major depressive episodes. JAMA Psychiatry. 2015;72(3):268–75.
45. Li D, Dai Y, Zhang ZY, et al. Systematic review and meta-analysis of traditional Chinese medicine in the treatment of constipation-predominant irritable bowel syndrome. PLoS ONE. 2017;12(12):e0189491.
46. Yanai M, Mochiki E, Ogawa A, et al. Intragastric administration of nikkomoto stimulates upper gastrointestinal motility and gastric emptying in conscious dogs. J Gastroenterol. 2013;48(5):611–9.
47. Shin SJ, Kim D, Kim JS, et al. Effects of Gastrodecoction on constipation in patients with acute ischemic stroke: a randomized controlled trial. J Tradit Chin Med. 2020;40(1):112–20.
48. Wang X, Zhang C, Zheng M, et al. Metabolomics analysis of L-arginine induced gastrointestinal motility disorder in rats using UPLC-MS after magnolol treatment. Front Pharmacol. 2019;10:183.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.